Last €2.40 EUR
Change Today +0.025 / 1.05%
Volume 0.0
YDO On Other Exchanges
Symbol
Exchange
NASDAQ GM
Stuttgart
As of 1:45 PM 10/20/14 All times are local (Market data is delayed by at least 15 minutes).

synta pharmaceuticals corp (YDO) Snapshot

Open
€2.35
Previous Close
€2.37
Day High
€2.43
Day Low
€2.35
52 Week High
02/25/14 - €5.28
52 Week Low
10/13/14 - €2.05
Market Cap
250.2M
Average Volume 10 Days
437.0
EPS TTM
--
Shares Outstanding
104.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SYNTA PHARMACEUTICALS CORP (YDO)

synta pharmaceuticals corp (YDO) Related Businessweek News

No Related Businessweek News Found

synta pharmaceuticals corp (YDO) Details

Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs for treating severe medical conditions, including cancer and chronic inflammatory diseases. The company has two drug candidates in clinical trials for treating multiple types of cancer and various drug candidates in the preclinical stage of development. Its lead drug candidate includes ganetespib, an Hsp90 inhibitor, which is in Phase III clinical trial for the treatment of non-small cell lung cancer; in Phase II clinical trial for patients with hormone receptor positive metastatic breast cancer; in Phase I clinical trial for the treatment of HER2 positive patients with metastatic breast cancer; in Phase II/III clinical trial for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome; and in Phase I/II trial of paclitaxel in combination with ganetespib in patients with platinum-resistant ovarian cancer. The company’s product pipeline also comprises Hsp90-inhibitor Drug Conjugate, a novel, proprietary small molecule cancer drug development program; and Elesclomol, a mitochondria-targeting agent that is in Phase 2 clinical trial for ovarian cancer. Its product pipeline in preclinical development stage for inflammatory diseases includes CRACM ion channel inhibitors for rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, allergy, transplant rejection, and other autoimmune diseases and inflammatory conditions; and IL-12/23 inhibitors for inflammatory and autoimmune diseases. Synta Pharmaceuticals Corp. was incorporated in 2000 and is based in Lexington, Massachusetts.

134 Employees
Last Reported Date: 03/11/14
Founded in 2000

synta pharmaceuticals corp (YDO) Top Compensated Officers

Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $349.7K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $486.3K
Vice President of Intellectual Property & Leg...
Total Annual Compensation: $353.6K
Compensation as of Fiscal Year 2013.

synta pharmaceuticals corp (YDO) Key Developments

Synta Pharmaceuticals Corp. Appoints Anne Whitaker as President, Chief Executive Officer and Member of the Board of Directors, Effective from September 2, 2014

Synta Pharmaceuticals Corp. announced that Anne Whitaker will join the company as President, Chief Executive Officer and a member of the company's Board of Directors effective September 2, 2014. Ms. Whitaker has more than 20 years of experience in the pharmaceutical industry, principally at GlaxoSmithKline and Sanofi including, most recently, the role of President, North America Pharmaceuticals, at Sanofi. As President, North America Pharmaceuticals, at Sanofi, Ms. Whitaker oversaw all pharmaceutical and consumer healthcare operations within the region, including the Diabetes, Oncology, Cardiovascular and other Patient Centered Units, Chattem (CHC), U.S. Market Access, U.S. Medical and Regulatory Affairs, Business Strategy, Planning & Operations and Canada Pharmaceuticals. She also served as a member of Sanofi's Global Leadership Team, Global Commercial Operations Committee and U.S. Regional Management Committee.

Synta Pharmaceuticals Corp. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Synta Pharmaceuticals Corp. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported a net loss of $22.3 million, or $0.24 per basic and diluted share compared to a net loss of $22.8 million, or $0.33 per basic and diluted share, for the same period in 2013. Loss from operations was $21.70 million compared to $22.06 million a year ago. For the six months, the company reported a net loss of $45.84 million, or $0.51 per basic and diluted share compared to a net loss of $43.52 million, or $0.63 per basic and diluted share, for the same period in 2013. Loss from operations was $44.61 million compared to $42.32 million a year ago.

Synta Pharmaceuticals Corp. to Report Q2, 2014 Results on Aug 06, 2014

Synta Pharmaceuticals Corp. announced that they will report Q2, 2014 results at 9:00 AM, Eastern Standard Time on Aug 06, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
YDO:GR €2.40 EUR +0.025

YDO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for YDO.
View Industry Companies
 

Industry Analysis

YDO

Industry Average

Valuation YDO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SYNTA PHARMACEUTICALS CORP, please visit www.syntapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.